Back to results
US 2024/0254249 A1Published application
Agonistic tnf receptor binding agents
AssigneesBioNTech SE, Genmab A/S
InventorsUgur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
Life of this patent
Estimating the term…
Abstract
The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
Claims16
-12. (canceled)
A binding agent that binds to OX40 (CD134), comprising:
- (a) the heavy chain complementarity determining region(s) HCDR1, HCDR2, and/or HCDR3, and/or
- the light chain complementarity determining region(s) LCDR1, LCDR2, and/or LCDR3
- of an antibody selected from the group consisting of AB134_1 to AB134_92 as shown in Table 8;
- and/or
- (b) the heavy chain variable domain (VH) or a variant or fragment thereof and/or the light chain variable domain (VL) or a variant fragment thereof
- of an antibody selected from the group consisting of AB134_1 to AB134_92 as shown in Table 8.
3 more elements
(canceled)
Dependencies are inferred from the claim text.